Roivant Sciences Ltd. (ROIV)
Develops drugs for autoimmune and lung diseases using novel molecular targets.
$33.73-0.03%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+198.2%
The outlook
ROIV is trading near the higher end of its 52-week range, well above both its 50- and 200-day moving averages. Analyst consensus leans strongly bullish, with an average price target about 14% above the current price. The stock shows solid upward momentum in its recent trend.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 10 analysts
Price trendAbove its 50- & 200-day averages
52-week range87% of the way from its 52-week low to high
Price targetAvg target +14% vs current price
Analyst price target
~12-month · 10 analysts$38.35average target+13.7% vs now
Now $33.73
Low $31.50High $42.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$24.26B
52-wk high
$37.00
52-wk low
$10.90
50-day avg
$32.18
200-day avg
$26.07
Trailing P/E
—